- Home
- ANIP
as 12-18-2024 11:30am EST
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | BAUDETTE |
| Market Cap: | 1.2B | IPO Year: | N/A |
| Target Price: | $77.33 | AVG Volume (30 days): | 253.7K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $52.00 - $70.81 | Next Earning Date: | 11-08-2024 |
| Revenue: | $555,456,000 | Revenue Growth: | 23.60% |
| Revenue Growth (this year): | 25.49% | Revenue Growth (next year): | 19.92% |
Stock Insider Trading Activity of ANI Pharmaceuticals Inc. (ANIP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Dec 13 '24 | Sell | $56.24 | 250 | $14,060.00 | 55,988 | |
| Davis Krista | ANIP | SVP, CHIEF HR OFFICER | Dec 11 '24 | Sell | $60.00 | 1,000 | $60,000.00 | 49,059 | |
| Lalwani Nikhil | ANIP | PRESIDENT & CEO | Nov 26 '24 | Sell | $58.13 | 33,481 | $1,941,442.30 | 373,859 | |
| Mutz Christopher | ANIP | HEAD OF RARE DISEASE | Nov 15 '24 | Sell | $57.70 | 6,500 | $375,050.00 | 76,777 | |
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Nov 13 '24 | Sell | $61.36 | 250 | $15,340.00 | 55,988 | |
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Oct 14 '24 | Sell | $57.19 | 250 | $14,297.50 | 55,988 |
Latest ANI Pharmaceuticals Inc. News
ANIP Breaking Stock News: Dive into ANIP Ticker-Specific Updates for Smart Investing
MT Newswires
7 days ago
Leerink Partners Initiates ANI Pharmaceuticals at Outperform With $80 Price Target
Argus Research
8 days ago
ANIP: Raising target price to $62.00
Zacks
12 days ago
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Argus Research
15 days ago
ANIP: Lowering target price to $60.00
Zacks
16 days ago
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?
MT Newswires
19 days ago
Ani Pharmaceuticals Insider Sold Shares Worth $1,941,442, According to a Recent SEC Filing
Argus Research
22 days ago
ANIP: Raising target price to $61.00
GlobeNewswire
22 days ago
ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference
Compare ANIP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANIP ANI Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.